Literature DB >> 17361384

Lessons from placebo effects in migraine treatment.

Fabio Antonaci1, Pierluigi Chimento, Hans-Christoph Diener, Grazia Sances, Giorgio Bono.   

Abstract

In medical research, the placebo effect is an important methodological tool. Placebo is given to participants in clinical trials, with the intention of mimicking an experimental intervention. The "nocebo" effect, on the other hand, is the phenomenon whereby a patient who believes that a treatment will cause harm actually does experience adverse effects. The placebo effect strongly influences the way the results of clinical trials are interpreted. Placebo responses vary with the choice of study design, the choice of primary outcome measure, the characteristics of the patients and the cultural setting in which the trial is conducted. In migraine trials, the placebo response is high, in terms of both efficacy and side effects. Although medical ethics committees are becoming increasingly resistant to the use of placebo in acute migraine trials, placebo nevertheless remains the pivotal comparator in trials of migraine medications.

Entities:  

Mesh:

Year:  2007        PMID: 17361384      PMCID: PMC3476117          DOI: 10.1007/s10194-007-0360-4

Source DB:  PubMed          Journal:  J Headache Pain        ISSN: 1129-2369            Impact factor:   7.277


  14 in total

Review 1.  Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics.

Authors:  Mengyuan Hou; Hongxia Liu; Yunfei Li; Ling Xu; Yingchun He; Yinghua Lv; Qingshan Zheng; Lujin Li
Journal:  Eur J Clin Pharmacol       Date:  2019-08-24       Impact factor: 2.953

Review 2.  Pain Modulation: From Conditioned Pain Modulation to Placebo and Nocebo Effects in Experimental and Clinical Pain.

Authors:  Janie Damien; Luana Colloca; Carmen-Édith Bellei-Rodriguez; Serge Marchand
Journal:  Int Rev Neurobiol       Date:  2018-08-14       Impact factor: 3.230

Review 3.  Meeting patient expectations in migraine treatment: what are the key endpoints?

Authors:  Fabio Antonaci; Grazia Sances; Elena Guaschino; Ilaria De Cillis; Giorgio Bono; Giuseppe Nappi
Journal:  J Headache Pain       Date:  2008-07-08       Impact factor: 7.277

Review 4.  Placebo and other psychological interactions in headache treatment.

Authors:  A Autret; D Valade; S Debiais
Journal:  J Headache Pain       Date:  2012-02-26       Impact factor: 7.277

5.  A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Duliang Soft Capsule in Patients with Chronic Daily Headache.

Authors:  Shengyuan Yu; Yueqing Hu; Qi Wan; Jiying Zhou; Xinfeng Liu; Xiangyang Qiao; Xiaosu Yang; Jiachun Feng; Kangning Chen; Xiaoping Pan; Qingwu Yang; Linsen Dou; Ming Liu; Yangmei Chen; Tingmin Yu; Juming Yu; Zhiwei Li; Xue Bai; Jingfeng Duan
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-26       Impact factor: 2.629

Review 6.  Is topiramate effective for migraine prevention in patients less than 18 years of age? A meta-analysis of randomized controlled trials.

Authors:  Kai Le; Dafan Yu; Jiamin Wang; Abdoulaye Idriss Ali; Yijing Guo
Journal:  J Headache Pain       Date:  2017-07-18       Impact factor: 7.277

7.  Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).

Authors:  Messoud Ashina; Joel Saper; Roger Cady; Barbara A Schaeffler; David M Biondi; Joe Hirman; Susan Pederson; Brent Allan; Jeff Smith
Journal:  Cephalalgia       Date:  2020-02-19       Impact factor: 6.292

8.  The nocebo effect of drugs.

Authors:  Sara Planès; Céline Villier; Michel Mallaret
Journal:  Pharmacol Res Perspect       Date:  2016-03-17

9.  Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.

Authors:  Richard B Lipton; Peter J Goadsby; Jeff Smith; Barbara A Schaeffler; David M Biondi; Joe Hirman; Susan Pederson; Brent Allan; Roger Cady
Journal:  Neurology       Date:  2020-03-24       Impact factor: 9.910

10.  Results and lessons learnt from a randomized controlled trial: prophylactic treatment of vestibular migraine with metoprolol (PROVEMIG).

Authors:  Otmar Bayer; Christine Adrion; Amani Al Tawil; Ulrich Mansmann; Michael Strupp
Journal:  Trials       Date:  2019-12-30       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.